Evidence map›Paper›PMID 40933889›Full record

ArticleFrontiers in oncology2025

Diagnosis and treatment of 33 patients with primary melanoma of the female reproductive system.

Yunge Gao, Jian Dong, Ligang Chen, Xin Guo, Lingling Liu, Weinan Guo, Cuiling Ma, Biliang Chen, Jian Wang, Xiaohui Lv

Abstract read
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yunge Gao *Department of Obstetrics and Gynecology, Xijing Hospital, Air Force Military Medical University, Shannxi, China.
Jian Dong *Department of Obstetrics and Gynecology, Xijing Hospital, Air Force Military Medical University, Shannxi, China.
Ligang Chen *Department of Obstetrics and Gynecology, Xijing Hospital, Air Force Military Medical University, Shannxi, China.
Xin GuoDepartment of Endoscopic Surgery, Air Force 986th Hospital, Air Force Military Medical University, Shannxi, China.
Lingling LiuDepartment of Dermatology, Xijing Hospital, Air Force Military Medical University, Shannxi, China.
Weinan GuoDepartment of Dermatology, Xijing Hospital, Air Force Military Medical University, Shannxi, China.
Cuiling MaDepartment of Dermatology, Xijing Hospital, Air Force Military Medical University, Shannxi, China.
Biliang ChenDepartment of Obstetrics and Gynecology, Xi'an People's Hospital (Xi'an Fourth Hospital), Shannxi, China.
Jian WangDepartment of Obstetrics and Gynecology, Xijing Hospital, Air Force Military Medical University, Shannxi, China.
Xiaohui LvDepartment of Obstetrics and Gynecology, Xijing Hospital, Air Force Military Medical University, Shannxi, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: This study aims to investigate the clinical and pathologic characteristics, treatment, and prognosis of primary melanoma in the female reproductive system. Methods: A retrospective analysis was performed using the clinical and pathological data of 33 patients with melanoma of the female lower genital tract who presented at the Department of Gynecology at Xijing Hospital of Air Force Military Medical University between June 2006 and July 2022. Pathological review and immunohistochemical staining were performed in all cases to confirm the diagnosis. Results: A total of 15 (45%) cases of primary melanoma involved the vulva, 16 (49%) involved the vagina, and two (6%) involved the cervix. The HMB-45 positive rate was 93%, the S-100 positive rate was 90%, and the Vim positive rate was 100%. Of these 33 cases, we had complete clinical information on 27 of them who received various comprehensive treatments including surgical treatment, postoperative radiotherapy, chemotherapy, immune therapy, or targeted therapy. Patients with stage III-IV comprised 67% of all cases, and the average duration of follow-up was 24 months. The 2-year recurrence rate was 82%, and the 3-year overall survival rate was 42%. Conclusions: The incidence of melanoma in the female reproductive system is low, and the prognosis is poor owing to the difficulty of early diagnosis and the high possibility of metastasis. Individualized comprehensive treatment like surgical treatment combined with immunotherapy can prolong the survival time and improve the prognosis of patients.

Indexed as

comprehensive treatmentfemale reproductive systemimmunotherapymelanomasurgery

Identifiers

PMID40933889
PMCPMC12417107

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.